Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Through its nimble Office of Therapeutics Alliances, NYU Langone Medical Center is harnessing the therapeutic potential of its world-class research by partnering with external experts in commercial drug discovery and development to advance the next generation of medical therapies and diagnostics.
The Center for Research and Advanced Studies (Cinvestav) is a national leader in scientific research, technology development and the formation of highly educated professionals in Mexico. Cinvestav is now expanding its reach globally with a nanoparticle-based therapy for Parkinson’s disease that represents an opportunity for international partnerships.
CALYM is a nonprofit research institute that offers a unique R&D approach in lymphoma treatments and diagnostics, spanning from new target identification to large international phase 3 clinical trials.
With two marketed products, two successful technology platforms and two advanced clinical candidates, Valneva is fast becoming the leading independent vaccine company.
Sanofi Pasteur, the vaccines division of Sanofi, is seeking partners with a common drive for excellence who will share the company’s pursuit of innovation.
Helperby’s antibiotic-resistance breakers are a powerful tool serving to prolong and boost antibiotic efficacy and should help counter the growing global crisis of antibiotic resistance.
The Antibody Lab is focused on improving screening for preeclampsia during pregnancy and is seeking strategic partners to change the current risk-assessment paradigm.
Eos Biosciences has developed the Eosome, a versatile drug delivery platform that maximizes efficacy through efficient intracellular delivery of therapeutic payloads. Eosomes can be adapted for many disease indications and for the delivery of a wide variety of drug modalities.
Google Ventures-backed Rani Therapeutics has developed a swallowable pill that injects biologic drugs directly into the intestine without degrading the drug in the stomach or gastrointestinal tract.
Coyote Biosciences has developed a range of miniaturized, portable and battery-powered molecular diagnostics instruments that provide point-of-care testing solutions—from detecting infectious diseases to profiling cancer—for health care providers and patients globally.
Repertoire Genesis is revealing new possibilities for personalized diagnosis and treatment with its technology platform for unbiased next-generation T and B cell receptor repertoire analysis.
Highland Therapeutics’ novel drug delivery platform is designed to offer control over the timing of drug release and the duration of therapeutic exposure, enabling dosing at night for treatment effect starting the moment the patient wakes and lasting throughout the day.
Portal Instruments’ needle-free and digitally controlled jet-injection device affords less injection-related pain and seamless integration with digital health care platforms, which could help improve patient tolerability and compliance.
